secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oruka Therapeutics, Inc. (ORKA)
CIK:        0000907654
Form:       8-K
Filed at:   2022-08-02T23:59:59+00:00
Accession:  0001564590-22-027494
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARCA biopharma Q2 net loss narrows to $3.1M; strategic review ongoing
---------------------------------------------------------------------

- Net loss $3.1M ($0.22/sh) vs $4.8M ($0.34/sh) year ago.
- Cash and equivalents $46.4M as of June 30, 2022, sufficient through end of 2023.
- R&D expenses fell to $1.5M from $3.6M due to completion of rNAPc2 trial enrollment.
- Strategic review with advisor Ladenburg Thalmann; exploring acquisition, merger, or other options.
- G&A expenses $1.7M, up $0.5M on higher professional fees and consulting costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/907654/000156459022027494/0001564590-22-027494-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/907654/000156459022027494/abio-8k_20220802.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-027494

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer